A highly specific, synthetic peptide vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist with potential antiangiogenic activity. Derived from human fibronectin with a proprietary protein engineering process, pegdinetanib may block the activation of VEGFR-2 by all known activating ligands, thereby inhibiting the growth of new tumor blood vessels. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More